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PURPOSE. Uveitis is a major cause of sight loss across the world. The reliable assessment of
intraocular inflammation in uveitis (‘disease activity’) is essential in order to score disease
severity and response to treatment. In this review, we describe how ‘quantitative imaging’,
the approach of using automated analysis and measurement algorithms across both standard
and emerging imaging modalities, can develop objective instrument-based measures of
disease activity.
METHODS. This is a narrative review based on searches of the current world literature using
terms related to quantitative imaging techniques in uveitis, supplemented by clinical trial
registry data, and expert knowledge of surrogate endpoints and outcome measures in
ophthalmology.
RESULTS. Current measures of disease activity are largely based on subjective clinical
estimation, and are relatively insensitive, with poor discrimination and reliability. The
development of quantitative imaging in uveitis is most established in the use of optical
coherence tomographic (OCT) measurement of central macular thickness (CMT) to measure
severity of macular edema (ME). The transformative effect of CMT in clinical assessment of
patients with ME provides a paradigm for the development and impact of other forms of
quantitative imaging. Quantitative imaging approaches are now being developed and
validated for other key inflammatory parameters such as anterior chamber cells, vitreous
haze, retinovascular leakage, and chorioretinal infiltrates.
CONCLUSIONS. As new forms of quantitative imaging in uveitis are proposed, the uveitis
community will need to evaluate these tools against the current subjective clinical estimates
and reach a new consensus for how disease activity in uveitis should be measured. The
development, validation, and adoption of sensitive and discriminatory measures of disease
activity is an unmet need that has the potential to transform both drug development and
routine clinical care for the patient with uveitis.
Keywords: uveitis, endpoint, surrogate, outcome measure, optical coherence tomography,
quantitative imaging
Uveitis, a group of conditions characterized by intraocularinflammation,1,2 is a major cause of blindness across the
world.3 The annual incidence of uveitis is estimated at 17.4
to 52.4 per 100,000 with a prevalence of approximately 38
to 114.5 per 100,000 general population.3–6 Although uveitis
may affect any age group, it peaks in the working-age
population,3 and thus has a high impact in terms of years of
visual loss, with some estimates of its socioeconomic impact
being on a par with diabetic retinopathy.7 Uveitis accounts
for approximately 10% to 15% of total blindness in the
developed world4,6 and up to 25% of blindness in the
developing world.8
The assessment of uveitis is a complex process. First, there
are the generic challenges common to the assessment of all
diseases, such as the choice of outcome, method of measure-
ment, and whose perspective it is measured from. Second,
there are issues, which specifically hamper the reliable
assessment of uveitis such as the heterogeneity of the range
of syndromes within uveitis, the variable manifestations even
within each syndrome (or within the same patient at different
times), and the limitations of many of our methods of
measuring outcomes. There has been increasing concern that
these challenges have limited drug development in uveitis, with
a number of high-profile late-phase clinical trials failing to meet
their primary endpoints, amid concern that it was the endpoint
that had ‘failed’ rather than the drug.9–12
In this review, we will consider the patient with uveitis
holistically, but with specific consideration of how a quantita-
tive approach to imaging may contribute to the assessment of
uveitis and may provide sensitive objective surrogate measures
for clinical trial purposes.
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PRINCIPLES OF ENDPOINTS IN UVEITIS
How should we assess a disease? A systematic review of
registered clinical trials identified 14 different types of
outcomes used as primary trial endpoints across 104 prospec-
tive interventional clinical trials of posterior-segment involving
uveitis.13 The authors proposed that outcome measures in
uveitis can be classified according to the ‘dimensions of the
disease’ they represent: disease activity, disease damage,
observed visual function (e.g., visual acuity [VA]), patient-
reported visual function, and quality of life. This series of
dimensions reflect both the timeline of disease, and a shift in
emphasis from the observed pathologic process to the
subjective experience of the disease by the patient.
All these dimensions are important aspects of the disease.
They are distinct and are not interchangeable. Different
interventions will require consideration of outcome measures
from the most appropriate dimension. For example, if an
intervention has been developed to reduce inflammation (the
dimension of disease activity), then its most immediate and
direct effect should be detectable using outcome measures
within that dimension. Efforts to evaluate such an intervention
through a downstream endpoint, such as visual acuity or
quality of life, however important these are, may be
unsuccessful due to the weaker beneficial effect seen (the
‘signal’), and the greater risk of confounding factors (‘noise’). A
relatively weak signal/noise ratio for a trial endpoint could be
compensated for by evaluating larger numbers of patients, but
this is particularly problematic in conditions, such as uveitis
where recruitment is challenging.9,11
There is an urgent need to develop better outcome
measures for the assessment of uveitis for two reasons: first
for use as trial endpoints in clinical studies with a view to drug
development and licensing; second to inform treatment
decisions in routine clinical practice. The US Food and Drug
Administration (FDA) provides guidance as to what we are
aiming for. They advise that a trial endpoint must be ‘well-
defined and reliable’ and that treatment benefit should be a
measure of how a patient ‘survives, feels, or functions’.14,15
Accordingly, there has been an emphasis in ophthalmic
licensing trials on visual acuity (as a measure of function),
although it should be noted that other measures of visual
function (such as visual field assessment) and patient-reported
outcome measures (PROMs) are also acceptable as a direct trial
endpoint. It will be evident however that most familiar
assessments of uveitis (other than VA) fall outside this remit,
and are therefore defined as surrogate measures of disease
activity. In the few consensus reviews of outcomes in uveitis,
measurement of inflammation was defined as an agreed
outcome measure in uveitis.1,11,16
The FDA requires a surrogate to be ‘reasonably likely, based
on epidemiologic, therapeutic, pathophysiologic, or other
evidence to predict clinical benefit’.17 Putting this into the
context of uveitis we would argue that any potential surrogate
measure should meet two essential criteria: (1) the surrogate
should be ‘biologically relevant’ given our understanding of the
pathophysiology of the disease, and (2) the surrogate should be
‘functionally relevant’ with evidence of downstream effect on
visual function, but recognizing that this effect may be delayed
and indirect. Providing that a surrogate has met both these
essential criteria, then it should be evaluated against desirable
criteria such as objectivity, repeatability, and sensitivity.18,19
CLINICALLY ASSESSED ENDPOINTS
The publication in 2005 of the recommendations of the
Standardization of Uveitis Nomenclature (SUN) workshop was
a major step forward for the field, and remains the current
paradigm in uveitis for both trials and routine clinical practice.1
Among other areas of standardization, this consensus state-
ment provided a single way of grading three aspects of disease
activity in uveitis: anterior chamber (AC) cells, AC flare, and
vitreous haze. The authors noted that prior to this date there
were at least four systems for AC cells,20–23 three for AC
flare20–23 and three for vitreous haze or debris.23–25 The SUN
workshop did also consider other aspects of disease activity,
but were unable to develop recommendations in these areas
due to lack of consensus.1 The role of visual acuity was
considered and guidance issued as to how it should be
reported in a trial context. The SUN recommendations have
been the vital foundation for the last decade of progress in
uveitis, but it should also be recognized that these guidelines
were never intended to be comprehensive and that a wide
range of outcomes are not covered by them. This includes
many aspects of disease activity, any measures of disease
damage, most aspects of measured visual function, and any
patient reported outcomes or quality of life.
A major limitation of our current clinical measures of
disease activity is that they are subjective. The National Eye
Institute (NEI) vitreous haze scale has had a pre-eminent place
as the uveitis activity measure preferred by the FDA for
effectiveness trials in posterior segment-involving uveitis. It is
based on the clinician’s estimate of the clarity of the optic disc
when viewed with the indirect ophthalmoscope and is
compared against a standard set of photographs as published
by Nussenblatt et al.25 in 1985. Although it has had value, it
does exemplify many of the problems typical of these clinical
measures. First, it is subjective, leading to significant scoring
variation between independent observers: Kempen et al.26
noted an interobserver agreement of k ¼ 0.53 (for exact
agreement) and k ¼ 0.75 (to be within 1 grade). Second, it is
noncontinuous leading to very large steps in disease activity
between categories. Third, it is poorly discriminatory at lower
levels of vitreous haze. Most cases of active uveitis tend to fall
within these lower levels, generally scoring þ0.5 or þ1 on the
ordinal scale (þ4 being the maximum).9,11,27
The limitations are most starkly seen when considered in a
clinical trial context. Due to expert concerns about the poor
discrimination of the NEI vitreous haze score, a change of at
least two steps is usually required to be considered significant
(which means that important smaller effects may be over-
looked), and inclusion criteria is usually set at a minimum of 2þ
vitreous haze (which dramatically limits recruitment). Finally,
the poor interobserver agreement has sometimes required two
independent observers for such studies, and has required
higher levels of recruitment to attempt to compensate for the
poor ‘signal:noise’ ratio of this endpoint.11,27
QUANTITATIVE IMAGING-BASED ENDPOINTS: OCT
CHANGES THE PARADIGM
In the decade or so since the SUN report, the introduction and
widespread adoption of high-resolution optical coherence
tomography (OCT) has provided a way of quantifying disease
processes through objective instrument-based measurements.28
Optical coherence tomography measurements of structure
provide noninvasive repeatable measures that are sensitive to
change in important disease processes. The commonest
examples in ophthalmology are the use of central macular
thickness (CMT) to measure the onset, severity and resolution of
macular edema (ME) or the use of retinal nerve fibre layer (RNFL)
thickness to detect the presence and progression of thinning of
that layer related to glaucomatous optic neuropathy.29 There are
a number of reasons why OCT has been particularly amenable to
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this role of serial quantification compared with some other
imaging modalities. First it is fast, noninvasive and well
tolerated—so it can be easily repeated at multiple visits. Second,
high contrast of different layers enables automated segmentation
from which parameters can be calculated (such as the thickness
of the retina or individual layers). Third, most commercial
systems utilize eye-tracking or alignment software such that
sequential scans can be overlain enabling precise calculation of
differences in thickness, and digital subtraction that enables this
to be visualized.
Interestingly OCT-derived parameters have become stan-
dard outcome measures in the clinic rather faster than they
have become acceptable as trial endpoints by the regulatory
authorities. Clinicians are comfortable with them as they self-
evidently measure structural changes that are direct conse-
quences of a pathologic process, but regulators such as the
FDA have pointed out that while OCT-derived endpoints are
‘well-defined and reliable’ they do not directly measure how a
patient ‘survives, feels or functions’. Demonstrating that these
types of imaging-based endpoints are indeed appropriate
surrogates for functional endpoints is a key step that has in
the past been overlooked by investigators and device
developers. It is however essential if we are going to move
from the limitations of our current subjective endpoints to the
‘well-defined and reliable’ objective endpoints that could
improve the sensitivity of clinical trials in uveitis.14,15,17
For the remainder of this review we will focus on those
aspects of intraocular inflammation that are generally regarded
as the most important indicators of disease activity in uveitis. In
the NEI-FDA Endpoint Workshop held in 2015, Holland and
associates proposed a short-list of manifestations that should be
regarded as the ‘fundamental signs of inflammation’: AC cells,
vitreous haze, retinal vascular leakage, retinal infiltrates, and
choroidal infiltrates.30 The exclusion of uveitic ME from that
list was based on advice from regulators that they regarded this
as a complication of the inflammation (rather than a sign of
disease activity per se), which could be multifactorial in origin
(i.e., not exclusively a sign of disease activity).
In routine practice however uveitic ME deserves consider-
ation in this list. There are good biological reasons to directly
link the development of ME to the inflammatory process (e.g.,
in the same way as retinovascular leakage and vitreous haze), it
associates with other measures of uveitis activity, and it
responds to treatment of the underlying inflammatory process
in a reversible way (unlike most other structural complications
of the disease). Uveitic ME is of particular importance to the
present discussion for two reasons: first, it is the single most
important reversible cause of sight-loss in uveitis that is
amenable to treatment with pharmacologic therapies (the
focus of most clinical trials); second the measurement of ME by
OCT is the prototypic demonstration of quantitative imaging in
uveitis. It is a glimpse of where we are headed.
CENTRAL MACULAR THICKNESS: OCT MEASUREMENT
OF MACULAR EDEMA
Macular edema is a leading cause of sight loss in uveitis. It
accounts for approximately one-third of blindness caused by the
disease.6 Prior to the advent of OCT, diagnosis depended on
biomicroscopy supported by fluorescein angiography (FA).
Detection by biomicroscopy is often difficult except in severe
cases and is not quantifiable. Assessment by FA was more
sensitive than biomicroscopy, but was again not easily quantifi-
able and had the disadvantage of requiring an invasive procedure
which reduced serial assessments.10 By providing high-resolu-
tion, cross-sectional images of ocular tissues in a noninvasive
manner, even early models of OCT showed the ability to provide
serial measurements of disease morphology (which could be
automated), and thus provide objective markers for clinical care
in a number of conditions including ME.28 In 1995, Hee et al.29
reported on a series of patients that included both diabetic
retinopathy patients and 25 patients with ME secondary to
retinal vein occlusion, uveitis, epiretinal membrane formation, or
cataract extraction, and noted that ‘serial optical coherence
tomographic examinations allowed tracking of both the longitu-
dinal progression of macular thickening and the resolution of ME
after laser photocoagulation’.29
A number of studies have compared OCT and FA, highlighting
the many advantages of OCT in the diagnosis of uveitic ME but
also demarcating its limitations. In their analysis of the utility of
these two investigations in the MUST trial, Kempen et al.31 noted
that the rate of ‘usable information’ was higher for OCT (90%; vs.
77% for FA) but that the agreement in diagnosis was only
moderate (K ¼ 0.44). This is essentially due to the differences
between anatomy and physiology: OCT measures structural
changes—macular thickening; FA measures leakage of dye across
the vessel wall. Although during active inflammation you will
commonly observe both macular thickening on OCT and
macular leakage on FA, it is perfectly possible to see either in
isolation. Indeed, the authors noted that of those with no
macular thickening on OCT, 40% cases demonstrated macular
leakage by FA; conversely of those with no macular leakage on
FA, 34% were shown to have macular thickening on OCT. It
should be noted that both modalities performed significantly
better than biomicroscopic evaluation alone.31
Importantly MUST is one of the few prospective uveitis
datasets that connects OCT-measured structural changes to
visual function, a vital step in its validation as a surrogate
endpoint. Taylor et al.32 reported that the presence of ME was
associated with both worse visual acuity and worse overall
visual field sensitivity, and that qualitative differences in edema
distribution was associated with differential impact on vision.
In a quantitative analysis of actual CMT values, Sugar et al.33
noted that each 100-lm reduction in CMT equated to a 6.5
letter increase in VA. A sensitivity analysis suggested that a 20%
reduction in macular thickness should be used as clinically
meaningful improvement in VA (sensitivity 77%, specificity
75% for 10 letter improvement). Other smaller studies have
also linked OCT changes to other functional outcomes such as
reading VA, reading speed, and central retinal sensitivity.34,35
Although CMT is the most widely used single OCT-derived
measure of macular status, it should be recognized that it is not
the only parameter available and that there is considerable
variation in methods for OCT quantification and reporting. Trials
using OCT estimation of ME include: (1) reporting ME as a binary
outcome, that is present/absent based on whether CMT is
greater or less than a prespecified threshold (which varies
according to the trial)36,37; the absolute change in CMT38; the
percentage change in CMT33; the change in CMT as a log score
(unpublished; clinicaltrials.gov number, NCT01314417); change
in cystoid area and height34; and estimation of retained area of
retinal tissue at the plexiform layer.39 It is also recognized that
there is more going on in uveitic ME than is captured by CMT
alone. Studies that assess the pattern of uveitic ME including
presence of cystoid spaces, presence of diffuse thickening, and
presence of subretinal fluid also have value and show the
differential affects of these patterns, and their quantification and
relative impact needs further exploration.32,40,41
AC CELLS: QUANTIFICATION OF ANTERIOR
INFLAMMATION THROUGH OCT
Measuring AC inflammation is required to assess the inflam-
matory activity of front of the eye. The current SUN grading
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system uses a slit-lamp microscope to count AC cells seen in a
131 mm beam of light.1 The cell count is then placed into one
of six ordinal grades. In the only study assessing this system,
interobserver agreement rates ranged from 51.4% to 57%
within the same grade at three different centers.26 Within 1
step, the agreement level increases, but this highlights the
imprecise feature of the current grading system—the high
likelihood that three or more trained observers would grade
the same patient at least two levels differently. Given this
variation, there is a need for quantification techniques to
measure AC inflammation that better separates different levels
of activity.1,11,26 In theory, imaging of the AC with OCT would
allow a consistent imaging method to determine the number of
cells in the AC. The ability of OCT imaging to identify cells in
the AC has been shown with both time-domain and spectral-
domain systems (Fig. 1).19,42–44 Using a spectral-domain
system, volume cube scans of the AC can be obtained.
Automated software can then be used to identify and count
the number of cells in this volumetric scan. Strict rules for
identification of cells in the algorithm eliminate the variability
of manual interpretation. Using this method, Sharma et al.19
published their experience in a prospective study of 76
patients. They defined a continuous measure of AC inflamma-
tion cells per millimeter cubed. High correlation between OCT
measurements and slit-lamp grading was found. More impor-
tantly, the relative lack of precision of slit-lamp–based grading
was highlighted with large ranges of the number of cells
identified by OCT within the same grade. This preliminary data
suggests that OCT automated quantification of AC cells may be
superior to clinical grading systems, but still requires
significant validation before becoming standard of care.
RETINOVASCULAR LEAKAGE: QUANTIFICATION OF
FLUORESCEIN ANGIOGRAPHIC FINDINGS
In humans and experimental animal models of uveitis,
posterior inflammation does not always reveal vitreous
haze.22,45,46 In experimental animal models of uveitis, retinal
vascular changes are almost universally observed, but vitreous
haze does not occur often.22,47–49 Indeed, grading systems of
experimental autoimmune uveitis (EAU) usually score for
cellular infiltration and damage to the retina but not haze.47,48
The presence of retinal vascular leakage on fluorescein
angiography is common finding in posterior segment inflam-
mation in humans.46,50,51 Given the variability of posterior
FIGURE 1. Optical coherence tomography line scans of two eyes, (A) with 2þAC cell inflammation and (B) with 4þAC cell inflammation. Arrows
denote hyperreflective spots representing inflammatory cells.
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segment findings in different etiologies of uveitis, the ability to
measure a variety of consequences of inflammation is
warranted. In order to properly measure retinal vascular
leakage, the use of ultra wide-field fundus fluorescein
angiography (UWFFA) is needed to capture as much of the
whole retina as possible. Using this technique a few studies
have shown the correlation between retinal vascular leakage
on wide-field fluorescein angiography and signs of activity. In
one retrospective review, the authors identified a correlation
between peripheral retinal vascular leakage and ME.51 In
another retrospective review of the use of wide-field angiog-
raphy in uveitis, the authors found the presence of leakage was
a sensitive measure of clinical activity (95%) and the lack of
leakage had high specificity for the absence of activity (93%).52
Correspondingly, the presence of retinal vascular leakage
correlated with increased AC cell and vitreous haze. Quanti-
fication of leakage on UWFFA is needed to use this as a
measure of inflammation. Both manual51 and automated
quantification of leakage have been described (Ehlers et al.,
manuscript under review). Using an automated algorithm to
identify leakage in uveitis patients has been shown to
discriminate between small changes at different time points
in the same patients.52 This highlights the potential for using
automated analysis of UWFFA images in uveitis patients as
another continuous measure of inflammation (Fig. 2).
VITREOUS INFLAMMATION: QUANTIFICATION OF
VITREOUS HAZE THROUGH OCT
Vitreous haze is a valuable sign of inflammation but, as alluded
to earlier, the clinical NEI Vitreous Haze score has a number of
major problems, which limit its value in both clinical practice
and as an endpoint for clinical trials. An objective instrument-
based measure equivalent to the use of CMT to measure ME
would have major advantages.
In 2014, Keane et al.53 published a proof-of-concept study,
which suggested that commercially available OCT could be
used for this purpose. This study of 60 participants (uveitis
patients and healthy controls) compared OCT derived vitreous
reflectivity data with the NEI Vitreous Haze Score. Spectral-
domain OCT images (Spectralis; Heidelberg Engineering,
Heidelberg, Germany) were taken using standard macular
settings, and analyzed using custom segmentation software
(‘‘OCTOR’’; Doheny Image Reading Center, Los Angeles, CA,
USA) leading to measurements of the vitreous signal intensity
and the RPE intensity (as internal reference value) from which
could be calculated the optical density ratio: ‘‘VIT/RPE-Relative
Intensity’’ (Fig. 3).
The key finding was that VIT/RPE-Relative Intensity was
significantly higher in uveitic eyes with known vitreous haze
than in uveitic eyes without haze or in healthy controls and
positively correlated with clinical vitreous haze as measured by
the NEI score. Other ocular characteristics of inflammation
also correlated with VIT/RPE-Relative Intensity, including AC
cells and AC flare. Critically, in the context of developing a tool
that is objective and reliable, measurement of VIT/RPE-Relative
Intensity showed a good degree of intergrader reproducibility
(95% limits of agreement: 0.019 to 0.016).53
Subsequent studies have validated this technique in a larger
cohort using a different OCT device (Cirrus; Carl Zeiss
Meditech, Dublin, CA, USA) and have developed an automated
version of the technique demonstrating how it could be used
in routine practice in a similar way to CMT (Fig. 3).54,55 More
recently the capacity of the test to detect responsiveness to
treatment was evaluated in a retrospective analysis of a cohort
who were undergoing subtenon triamcinolone acetonide for
uveitic ME. Sreekantham, et al.18 reported that in their cohort
of 22 eyes, mean VIT/RPE relative intensity improved from
0.139 to 0.053 with treatment and that this was highly
statistically significant (P ¼ 3 3 105). The authors noted that
the absolute measures of vitreous activity showed similar
improvement and that the reduction in the VIT/RPE relative
intensity was not therefore an artifact arising from changes in
the RPE visualization caused by resolution of the overlying
fluid.18
While acknowledging that this was a retrospective analysis,
the sensitivity of that small study to detect a change at a highly
statistically significant level shows how the acceptance of OCT-
derived objective indices would transform the landscape of
clinical trials in uveitis, enabling them to be smaller, cheaper,
and more efficient.
FIGURE 2. Ultra wide-field fluorescein images late frames with leakage measured with an automated algorithm at two separate time-points,
pretreatment (left) and during treatment (right). Leakage identified in green, blood vessels in red. These images are dewarped eliminating the
peripheral distortion. Leakage area measures, 22.8% (left) and 11.3% (right).
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FIGURE 3. Quantitative assessment of the vitreous using OCT at initial presentation in a 57-year-old patient with idiopathic panuveitis and a clinical
NEI Vitreous Haze Score of 2þ. Pretreatment: (A) OCT-scan revealing widespread intravitreal cellular infiltrates and diffusely increased vitreous
signal intensity. (B) Post segmentation of the vitreous compartment (boundaries: vitreous top to internal limiting membrane [ILM]) and the RPE
(boundaries: RPE-inner to RPE-outer), with a resulting vitreous signal intensity: RPE relative intensity (OCT-VIT:RPE) of 0.355. Post treatment with
oral corticosteroids: (C) OCT-scan revealing a significant reduction in both vitreous haze and inflammatory cells. (D) Post segmentation of the
vitreous compartment, with OCT-VIT:RPE of 0.127. (E) Potential application to clinical practice. Monitoring of visual acuity (number of letters
read), OCT-VIT:RPE (measuring vitreous inflammation) and CMT (measuring ME) over 84 weeks in the right eye of a 32-year-old patient with
panuveitis secondary to sarcoidosis. At baseline he reported reduced vision, and had clinical evidence of active panuveitis with NEI vitreous haze
score of 1þ, and ME. He was treated with high-dose oral corticosteroids (orange arrow) with resolution of inflammation and CMT returning to a
normal value of 240 lm. A subsequent recurrence was treated with pulsed intravenous methylprednisolone (red arrow). It is noted that changes in
OCT-VIT:RPE may anticipate other signs of inflammation including ME; in this example it is seen to be an early indicator both of response to
treatment (week 6) and of loss of control of inflammation (week 48).
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CHORIORETINAL LESIONS: QUANTIFICATION OF ‘SPOTS’
Modern fundus cameras and ultra wide-field imaging such as the
Optos system (Optos Plc, Dunfermline, Scotland, UK) enable
rapid and reliable longitudinal documentation of chorioretinal
lesions. For those forms of uveitis characterized by choroidal or
retinal infiltrates, this is a valuable tool for detecting disease
activity.56,57 However, it is limited by being, for the most part, a
subjective assessment based on the observer’s judgment in
identifying new spots, change in spot area, or changes in the
spot boundary. A system of automated quantification of lesion
area and other lesion characteristics would be highly valuable.
FIGURE 4. Comparative infrared, spectral-domain OCT images, and retinal thickness maps from the left eye of a 43-year-old female patient with
active punctate inner choroidopathy taken with the Heidelberg Spectralis system. (A) Spectral-domain OCT during a symptomatic flare-up shows
focal disruption of the RPE and ellipsoid zone associated with a dome-shaped hyperreflective area. Heidelberg Eye Explorer software provides
retinal thickness maps showing increase in retinal thickness due to the number, size, and intensity of ‘hot spots’ compared with reference with
automated quantitative analysis of average change in different subfields of the macular grid, and with operator-dependent measurement of point-
change over individual lesions. Spectral-domain OCT repeated 23 days after intravitreal injection of triamcinolone acetonide shows involution of the
active lesion and resolution of the ‘hot spots’ on the corresponding retinal thickness maps compared with the same reference scan, together with
quantitative analysis of retinal thickness topography. Further details available at Madhusdhan et al.58
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For chorioretinal disease confined mainly to the posterior
pole, quantitative OCT analysis of chorioretinal lesions using
existing commercial software may be helpful. In their
dedicated punctate inner choroidopathy (PIC) clinic, Madhu-
sudhan et al.58 use this technique as standard, demonstrating
how even mild flares of disease could consistently be detected
and quantitated on sequential thickness maps (Fig. 4).
Optical coherence tomography is also being increasingly
used outside the posterior pole initially through eccentric
fixation, such as the standardized extramacular approach
described by Keane et al.,59 and more recently through advances
in hardware such as swept-source devices or the wide-field
Heidelberg Spectralis lens system. As wide-field OCT becomes
more widely adopted, it will be important that parallel
development of software ensures that users are presented with
easily interpretable data arising from the automated sequential
tracking and measurement of these lesions. Ideally, this process
will be undertaken across all imaging modalities, such that
change can be presented multidimensionally whether based on
three-dimensional OCT parameters or two-dimensional mea-
sures arising from wavelength-specific reflectance or autofluo-
rescence. Ensuring that this wealth of data is easily and quickly
interpretable will be key.
QUANTITATIVE IMAGING: VALIDATION AND ADOPTION
Although these automated measures appear to provide some
superiority to the current grading systems, validation of these
methods is needed prior to wide-scale acceptance. One may
argue that the current grading systems lack the tenets to be
considered gold standards,19 but as there are currently
accepted ones, the burden will be on new grading systems
to display reliability and validity. Several groups have published
the requirements for a tool to be considered valid and reliable.
The Outcome Measures in Rheumatology (OMERACT) initia-
tive has worked to improve outcome measures within
rheumatology.60,61 The crucial component in any outcome is
establishing a validated and reliable measurement instrument
test.61 OMERACT developed a filter that summarizes the
qualities of an excellent valid instrument measure in three
words: truth, discrimination, and feasibility. Truth—does a test
measure what is intended? Discrimination—does the measure
discriminate between situations of interest? Feasibility—can
the measure be applied easily, given constraints of time,
money, and interpretability?60,61
Additionally, the COnsensus-based Standards for the selec-
tion of health Measurement INstruments (COSMIN) initiative
developed standards for evaluating measurement properties of
health measurement instruments.62–64 The three domains to
examine include reliability, validity, and responsiveness.
Reliability is measured using intra-observer agreement, inter-
observer agreement, intraclass correlation, and measurement
error. Validity is assessed by properties of content, construct,
and criterion validity. Finally, responsiveness is judged by the
ability to detect change over time in the construct to be
measured.62–64
Having developed and validated appropriate outcome
measures for use as endpoints in the assessment of uveitis,
the remaining challenge will be to ensure widespread
adoption. Inconsistent use of outcomes reduces the ability to
compare trials and aggregate data, limits meta-analysis, and is a
major cause of research waste. One way of tackling this,
espoused by both OMERACT and the Core Outcome Measures
in Effectiveness Trials (COMET) initiative, is to develop core
outcome sets (COS).61,65 These are standardized sets of
outcomes that represent the minimum that should be
measured and reported in all clinical trials, other research, or
audits for a specific condition. The COS is not exclusive (other
outcome measures can be added as appropriate per trial) and
does not dictate which outcome should be the primary
endpoint. The COS should engage all stakeholders from the
outset. For example, the COS for posterior-segment involving
uveitis currently in development will involve patients, carers,
expert clinicians, and policy makers through an international
Delphi process and consensus meeting to ensure that the final
agreed COS has value to the whole community.66 It is to be
hoped that the rapid onward development and validation of
automated imaging quantification systems would mean that
they would be eligible for inclusion in future COS for uveitis,
and thereby rapidly adopted as standard.
CONCLUSIONS
The use of quantitative imaging in uveitis, and the develop-
ment of these parameters as endpoints, is for the most part still
in a relatively early phase. The unmet need is recognized, and
the path to adoption is becoming clearer. Just as these days it
would seem absurd to estimate the severity of ME by
biomicroscopy alone, so in a few years time it will seem
bizarre and antiquated to try to quantify AC cells, vitreous haze,
or any other aspect of inflammation by subjective clinical
estimation. This move to objective instrument-based quantifi-
cation does not mean that the patient with uveitis can be
reduced to a few key indices. Central macular thickness is
indeed only one parameter in the description of a patient with
ME; it does not purport to be a holistic assessment of the
functional, psychological, or societal consequences of the
disease. But it is an extremely useful parameter, the use of
which enables us to assess severity, progression and response
to treatment at a tissue level, in a way that was never possible
prior to the advent of OCT. In a similar way over the next few
years we can expect quantitative imaging to replace current
clinical estimates and provide the sensitive reliable objective
outcome measures that will transform the practice of uveitis,
the design of future trials, and the prospects of patients with
sight-threatening inflammatory disease.
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